Our patient’s clopidogrel treatment failure may be due to a combination of impaired clopidogrel metabolism (due to presence of no-function CYP2C19 variant) and decreased inhibition of platelet reactivity (possibly by DM and obesity). The gene discussed is CYP2C19; the disease is obesity disorder.